Epilepsy with Myoclonic Absences: A Patient Guide

Epilepsy with Myoclonic Absences (EMA) is a rare and distinct childhood epilepsy syndrome that requires a specialized approach to both diagnosis and care. Unlike common “staring spells,” EMA is defined by the simultaneous occurrence of a brief loss of awareness—the absence—and rhythmic, repetitive jerking of the muscles, known as myoclonus ^[1]. During these episodes, parents often notice their child’s arms rhythmically lifting upward and away from the body, a movement called tonic abduction ^[2]. Because these physical jerks are so prominent, the condition can sometimes be mistaken for other types of seizures, but the underlying cause is a synchronized misfiring of the brain’s widely distributed, bilateral electrical networks ^[3].

At the heart of this syndrome is a specific “conversation” between the brain’s relay station, the thalamus, and its outer processing layer, the cortex ^[4]. When this corticothalamic network misfires, it frequently produces a characteristic 3-Hz “spike-and-wave” pattern on an EEG (brain wave test) ^[5]. While the physical movements may look similar to other conditions, this specific electrical signature—when correlated with the muscle jerks—is what allows a pediatric epileptologist to identify the syndrome and distinguish it from more common forms of childhood epilepsy, though the 3-Hz pattern is not unique to EMA alone ^[6].

Important Safety Rule: Never stop or change your child’s antiseizure medication abruptly or without consulting the prescribing doctor, as this can trigger severe or prolonged seizures.

The cause of EMA can sometimes be rooted in a child’s unique genetic makeup. While there is no single “EMA gene,” some children are found to have variations in genes like SYNGAP1, SETD1B, or SLC2A1, which are often rare causes or associated with overlapping epilepsy phenotypes ^[6][7]. Because the underlying cause is varied, comprehensive genetic testing is often considered when epilepsy is early-onset, when development is atypical, or when seizures are drug-resistant ^[8]. Identifying a specific genetic driver helps the medical team understand why the seizures are happening and can sometimes—though not always—point toward more effective treatment strategies.

Managing EMA is a journey that often involves multiple types of support beyond just controlling the seizures themselves. Treatment typically focuses on broad-spectrum medications, such as valproate or lamotrigine, which can treat both the staring and the jerking components of the syndrome ^[5][9]. It is equally important to know which medications to avoid, as some common epilepsy drugs can actually make these specific jerks worse ^[10]. Because EMA is often difficult to treat and can impact a child’s development, the best outcomes are achieved through a collaborative care team that includes specialists in neurology, genetics, and developmental therapy ^[11].

While a diagnosis of EMA brings significant challenges, it also provides a roadmap for the future. By moving from a broad description of “seizures” to a specific understanding of this rare syndrome, you and your medical team can focus on the most effective treatments and the right developmental supports. With the guidance of specialists and a clear plan for safety and education, you can build a stable environment that supports your child’s quality of life ^[12].